With the help of the Internet, the market size of out-of-hospital drug use is expected to sprint by 500 billion yuan

Pharmaceutical Network Market Analysis: Prescription outflow is mainly caused by in-hospital steering line or offline out-of-hospital terminals.
data show that the total size of China's prescription outflow market is nearly 300 billion yuan, with an average annual outflow of 40 billion yuan to 70 billion yuan.
industry said that this year by the impact of a special period, the advantages of Internet health care gradually highlighted, is expected to be the help of the Internet, the size of the out-of-hospital drug market is expected to sprint 500 billion yuan.
the background of policies such as collecting and collecting drugs to push down prices, the retail market outside the hospital has also become a new position for multinational pharmaceutical companies and local pharmaceutical companies to compete.
, for example, AstraZeneza has chosen to move towards the retail market after the fat-lowering drug "Rishuvastatin Calcium" failed to be tendered for the "4 plus 7" collection and expansion.
first quarter of this year, AstraZenecon's sales of Rishuvastatin calcium reached 410 million yuan in the pharmacy market, up nearly 70% from the same period last year, according to CMH.
addition, multinational drug companies such as Pfizer, Merca East and Roche are investing more in retail pharmacies, and Mercedon has even set up a dedicated retail pharmacy development team.
, under the trend of Internet medical treatment, the pharmaceutical circulation industry will accelerate the integration of the line.
Overlay management and scale advantages, the industry expects the advantages of large pharmacy chains will be further highlighted, and small and medium-sized enterprises that do not have the viability will be shuffle out or merged, the future industry concentration will accelerate, in recent years, the pharmacy retail industry chain rate is also rapidly rising, from 35.58 percent in 2008 to 50.05 percent in 2017.
for the hundreds of billions of out-of-hospital retail market, the country's large pharmacy chains have also issued a prescription drug business strategy, such as Yifeng Pharmacy said it will expand the prescription drug market from three directions.
First, to improve the company's operating capacity and professional services capacity, to undertake prescription outflow, second, with the pharmaceutical companies in-depth cooperation to undertake prescription outflow, third, self-built Internet hospital platform, to undertake prescription sources and terminals.
it is worth mentioning that transformation and upgrading is a major issue facing retail enterprises, and the provision of licensed pharmacists is one of the major difficulties.
in accordance with the requirements, under normal circumstances, retail pharmacies should be satisfied with the opening of the business have a practicing pharmacist on the job, each need to equip at least 2 practicing pharmacists.
but China's practicing pharmacists gap is large, not enough, difficult to equip the problem still exists.
2019, there were 6,701 drug retail chains, 290,000 retail chain stores and 234,000 retail pharmacies nationwide, according to the Company's statistics.
, more than 460,000 pharmacists were registered in retail pharmacies nationwide by the end of 2019, according to data released by the National Drug Administration's Center for the Qualification of Practicing Pharmacists.
with the implementation of the pharmacy classification classification management policy and the future promulgation of the Pharmacist Act, the industry is expected to continue to expand the gap of practicing pharmacists in the future.
Some industry insiders pointed out that, although in August this year, "on the regulation of drug retail enterprises equipped with the use of licensed pharmacists notice (draft for comments)" issued, the document for the current part of the practice of pharmacists are not enough, difficult to equipped with the actual situation, put forward that "the provincial drug regulatory departments in the existing pharmaceutical regulatory departments do not reduce the overall proportion of existing practicing pharmacists, can formulate the implementation of differentiated provisions of the use of licensed pharmacists policy, and set a transition period."
the transition period, pharmaceutical retail enterprises are allowed to equip other pharmaceutical technicians to assume the duties of practicing pharmacists in areas where there is a significant gap in practicing pharmacists, and the transition period does not exceed 2025.
" But on the whole, the future pharmacy equipped with licensed pharmacists is an inescapable thing, a very real problem is that many pharmaceutical retail enterprises can no longer support high labor costs, so overall, many small and medium-sized enterprises are difficult to bear high costs.
in general, it will take time to prove whether the transition from hospital to out-of-hospital sales can bring real increments for pharmaceutical companies.
for pharmacies, however, large pharmacy chains may be expected to benefit from the trend of industry concentration, while competition in the market will intensify.